ATE252113T1 - Verwendung von wnt polypeptiden - Google Patents

Verwendung von wnt polypeptiden

Info

Publication number
ATE252113T1
ATE252113T1 AT97936448T AT97936448T ATE252113T1 AT E252113 T1 ATE252113 T1 AT E252113T1 AT 97936448 T AT97936448 T AT 97936448T AT 97936448 T AT97936448 T AT 97936448T AT E252113 T1 ATE252113 T1 AT E252113T1
Authority
AT
Austria
Prior art keywords
wnt polypeptides
wnt
polypeptides
hematopoiesis
differentiation
Prior art date
Application number
AT97936448T
Other languages
English (en)
Inventor
William Matthews
Timothy W Austin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE252113T1 publication Critical patent/ATE252113T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97936448T 1996-08-16 1997-08-07 Verwendung von wnt polypeptiden ATE252113T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/696,566 US5851984A (en) 1996-08-16 1996-08-16 Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
PCT/US1997/013910 WO1998006747A2 (en) 1996-08-16 1997-08-07 USE OF WNT POLYPEPTIDES

Publications (1)

Publication Number Publication Date
ATE252113T1 true ATE252113T1 (de) 2003-11-15

Family

ID=24797608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936448T ATE252113T1 (de) 1996-08-16 1997-08-07 Verwendung von wnt polypeptiden

Country Status (9)

Country Link
US (1) US5851984A (de)
EP (1) EP0918794B1 (de)
JP (1) JP3759623B2 (de)
AT (1) ATE252113T1 (de)
AU (1) AU721947B2 (de)
DE (1) DE69725587T2 (de)
ES (1) ES2208943T3 (de)
IL (2) IL128129A0 (de)
WO (1) WO1998006747A2 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
BR9910023A (pt) * 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
BR9914465A (pt) 1998-09-29 2001-10-09 Gamida Cell Ltd Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células
US6485972B1 (en) * 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
BR9905867A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
US20030104561A1 (en) * 1999-02-09 2003-06-05 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000061630A1 (en) * 1999-04-08 2000-10-19 President And Fellows Of Harvard College Induction of kidney tubule formation
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
AU784513B2 (en) * 2000-01-18 2006-04-27 Board Of Trustees Of The Leland Stanford Junior University Expansion of stem and progenitor cells by beta-catenin
US6653448B1 (en) * 2000-03-29 2003-11-25 Curagen Corporation Wnt-7B-like polypeptides and nucleic acids encoding same
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
WO2002000171A2 (en) * 2000-06-26 2002-01-03 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
EP1178317B1 (de) 2000-07-24 2004-11-10 Health Research, Inc. Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US7311904B2 (en) 2001-02-14 2007-12-25 Anthrogenesis Corporation Tissue matrices comprising placental stem cells, and methods of making the same
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
JP4029041B2 (ja) * 2001-01-10 2008-01-09 アメリカ合衆国 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
IL157350A0 (en) 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002308557A1 (en) * 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7101693B2 (en) * 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2003076613A1 (en) * 2002-03-11 2003-09-18 Reprocell Inc. Protein sustaining undifferentiated stem cells as such
DE10212867B4 (de) * 2002-03-22 2005-07-21 Hans Prof. Dr. Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1501928A4 (de) * 2002-05-09 2007-08-15 Univ New York Melanogenesetest
CA2487058C (en) * 2002-05-17 2015-04-14 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
CA2488013A1 (en) * 2002-05-30 2003-12-11 Celgene Corporation Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
EP1530418A4 (de) * 2002-05-31 2005-10-12 Univ Leland Stanford Junior Verfahren zur identifizierung und isolierung von stammzellen und krebsstammzellen
RU2329274C2 (ru) * 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
EP1560916A1 (de) * 2002-11-08 2005-08-10 ReproCELL Inc. Mittel zur expansion von stammzellen
WO2004047757A2 (en) * 2002-11-21 2004-06-10 University Of Massachusets Diagnosing and treating hematopoietic cancers
JP2006509770A (ja) 2002-11-26 2006-03-23 アンソロジェネシス コーポレーション 細胞治療学、細胞治療単位、およびそれらを利用した治療法
CA2507581A1 (en) * 2002-12-06 2004-06-24 The Board Of Trustees Of The Leland Stanford Junior University Protection of stem cells from cytotoxic agents by modulation of .beta.-catenin signaling pathways
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
CA2515552C (en) * 2002-12-27 2012-09-18 Mitsubishi Heavy Industries, Ltd. Method and apparatus of cultivating multipotent stem cell
US7153832B2 (en) * 2003-04-07 2006-12-26 The Board Of Trustees Of The Leland Stanford Junior University Compositions of active Wnt protein
WO2004094610A2 (en) * 2003-04-21 2004-11-04 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
ES2433493T3 (es) 2003-06-25 2013-12-11 Ottawa Hospital Research Institute Métodos y composiciones para modular el crecimiento de células pluripotenciales y la diferenciación
WO2004113380A1 (en) * 2003-06-25 2004-12-29 Ottawa Health Research Institute Use of cardiotrophin to modulate stem cell proliferation
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CA2558738C (en) 2004-03-11 2013-02-05 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
CN102302787A (zh) * 2004-03-11 2012-01-04 费森尤斯卡比德国有限公司 羟烷基淀粉和蛋白质的接合物
CN1981054A (zh) * 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
EP1799812A4 (de) 2004-09-16 2009-09-09 Gamida Cell Ltd Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
WO2006034602A1 (en) * 2004-09-28 2006-04-06 Beijing Institute Of Transfusion Medicine Methods for porliferation of hematopoietic stem/progenitor cell in vitro
AU2005295269B2 (en) * 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
AU2012200875B2 (en) * 2004-12-30 2012-08-30 Robarts Research Institute Methods for regulation of stem cells
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
WO2007030658A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Compositions useful for and methods of modulating angiogenesis
EP1762250A1 (de) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
AU2006304277B2 (en) * 2005-10-13 2012-07-05 Celularity Inc. Immunomodulation using placental stem cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8455250B2 (en) 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
ES2671355T3 (es) 2005-12-29 2018-06-06 Anthrogenesis Corporation Poblaciones de células madre placentarias
EP2129775A1 (de) 2007-02-12 2009-12-09 Anthrogenesis Corporation Hepatocyten und chondrocyten aus adhärenten plazentastammzellen sowie cd34+, cd45- plazentastammzellenangereicherte zellpopulationen
SI2120977T1 (sl) 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
WO2008109119A2 (en) * 2007-03-05 2008-09-12 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods of use thereof
JP5646990B2 (ja) * 2007-04-23 2014-12-24 ストワーズ インスティテュート フォー メディカル リサーチ 幹細胞自己複製のための方法及び組成物
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
RS53841B1 (sr) 2007-09-28 2015-06-30 Anthrogenesis Corporation Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
MX2011001992A (es) 2008-08-22 2011-03-29 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
CA2743566C (en) 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
SI2556145T1 (sl) 2010-04-07 2017-01-31 Anthrogenesis Corporation Angiogeneza z uporabo placentnih matičnih celic
AU2011237743A1 (en) 2010-04-08 2012-11-01 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011146574A1 (en) 2010-05-18 2011-11-24 Neumedicines, Inc. Il-12 formulations for enhancing hematopoiesis
CN107828727A (zh) 2010-07-13 2018-03-23 人类起源公司 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
WO2012034070A1 (en) 2010-09-09 2012-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of liposomal wnt compositions to enhance osseointegration
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (de) 2011-06-01 2019-02-20 Celularity, Inc. Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
BR112014020119A2 (pt) 2012-02-13 2020-10-27 Gamida-Cell Ltd cultura de células-tronco mesenquimais
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US20180360025A1 (en) * 2015-07-22 2018-12-20 Ramot At Tel-Aviv University Ltd. Article of manufacture and methods for increasing survival of red blood cells
KR20190115057A (ko) * 2017-02-10 2019-10-10 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (de) *
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
USRE30985E (en) * 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) * 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) * 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) * 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) * 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
GB8516415D0 (en) * 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (de) * 1986-03-07 1990-02-05 Massachusetts Inst Technology Verfahren zur verbesserung der glykoproteinstabilität.
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) * 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) * 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (de) * 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. Transkriptionsaktivator des 780 T-DNA-Gens
ATE105585T1 (de) * 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
AU4005289A (en) * 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
DE68925971T2 (de) * 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE68927344T2 (de) * 1989-04-28 1997-02-20 Rhein Biotech Proz & Prod Gmbh Hefezellen der Gattung-Schwanniomyces
FR2646437B1 (fr) * 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (de) * 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DK168302B1 (da) * 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
FR2649120B1 (fr) * 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE131872T1 (de) * 1989-11-22 1996-01-15 Genentech Inc Latenz assoziierte peptide und deren verwendung
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH06507398A (ja) * 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5672346A (en) * 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
DE69308573T2 (de) * 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
SE9203831L (sv) * 1992-12-18 1994-02-21 Sp Wm Dricksvatten Ab Anordning för avskiljande av emulsioner genom elektrokemisk fällning
WO1995017416A1 (en) * 1993-12-22 1995-06-29 Merck & Co., Inc. Dna encoding the wnt-x growth factor
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof

Also Published As

Publication number Publication date
ES2208943T3 (es) 2004-06-16
JP3759623B2 (ja) 2006-03-29
DE69725587T2 (de) 2004-07-29
JP2000516466A (ja) 2000-12-12
WO1998006747A2 (en) 1998-02-19
US5851984A (en) 1998-12-22
WO1998006747A3 (en) 1998-05-07
IL128129A0 (en) 1999-11-30
EP0918794A2 (de) 1999-06-02
EP0918794B1 (de) 2003-10-15
AU721947B2 (en) 2000-07-20
AU3911297A (en) 1998-03-06
IL128129A (en) 2006-12-31
DE69725587D1 (de) 2003-11-20

Similar Documents

Publication Publication Date Title
DE69725587D1 (de) Verwendung von wnt polypeptiden
DE69527540D1 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
AU1750297A (en) Humanized green fluorescent protein genes and methods
IL148512A0 (en) Methods for making recombinant proteins using apoptosis inhibitors
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
DK0772624T3 (da) Interleukin-15
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
DK506488A (da) Fremgangsmaade til dyrkning af rekombinante celler, vaertscelle til anvendelse ved fremgangsmaaden og kultur omfattende vaertscellen
PT720482E (pt) Prosaposina e peptidos derivados da citocina utilizados como agentes
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
DK0845963T3 (da) Anvendelse af autologe dermale fibroblaster til reparation af hud- og blødvævsdefekter
NZ516400A (en) Stable factor VIII compositions
EP0559769A4 (en) Heparin binding mitogen with homology to epidermal growth factor (egf)
IL148008A0 (en) Conditional immortalisation of cells
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DE69526395D1 (de) Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
DE69529674D1 (de) Biologisch aktive ligande der eph familie
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
CA2262469A1 (en) Uses for wnt polypeptides
ATE253634T1 (de) Polypeptide mit serotoninerger (5ht5a) rezeptor- aktivität, für sie kodierende nukleinsäuren und ihre verwendung
IL108584A0 (en) Cloning of interferon - alpha beta binding protein
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties